Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City

BACKGROUND: Tocilizumab and baricitinib are immunomodulators that have been repurposed for the treatment of coronavirus disease 2019 (COVID-19). Whether one medication should be preferred over the other has not been established. METHODS: This multicenter retrospective cohort study comprised hospital...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunny, Subin, Tran, Ami, Lee, Jennifer, Abdallah, Marie, Chaudhry, Nimra, Quale, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442059/
https://www.ncbi.nlm.nih.gov/pubmed/37608917
http://dx.doi.org/10.1093/ofid/ofad426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442059/
https://www.ncbi.nlm.nih.gov/pubmed/37608917
http://dx.doi.org/10.1093/ofid/ofad426

Ejemplares similares